Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
23.25
+0.41 (1.80%)
Nov 5, 2024, 3:49 PM EST - Market open

Company Description

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases.

The company’s product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.

It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease.

The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Viridian Therapeutics, Inc.
Viridian Therapeutics logo
Country United States
Founded 2006
Industry Biotechnology
Sector Healthcare
Employees 94
CEO Stephen Mahoney

Contact Details

Address:
221 Crescent Street, Suite 401
Waltham, Massachusetts 02453
United States
Phone 617 272 4600
Website viridiantherapeutics.com

Stock Details

Ticker Symbol VRDN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001590750
CUSIP Number 92790C104
ISIN Number US92790C1045
Employer ID 47-1187261
SIC Code 8071

Key Executives

Name Position
Stephen F. Mahoney J.D., MBA Chief Executive Officer, President and Director
Seth Harmon Senior Vice President of Finance and Accounting, Principal Financial and Accounting Officer
Thomas W. Beetham J.D., MBA Chief Operating Officer
Dr. Eric N. Olson Ph.D. Co-Founder and Chairman of Scientific Advisory Board
Dr. Michael R. Bristow M.D., Ph.D. Co-Founder and Member of the Scientific Advisory Board
Dr. Marvin H. Caruthers Ph.D. Co-Founder and Scientific Advisory Board Member
Vahe Bedian Ph.D. Co-Founder and Scientific Advisor
Jennifer Tousignant J.D. Chief Legal Officer
John A. Jordan Vice President of Investor Relations and Corporate Communications
Melissa Manno Chief Human Resources Officer

Latest SEC Filings

Date Type Title
Oct 18, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Sep 17, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Sep 13, 2024 424B5 Filing
Sep 12, 2024 8-K Current Report
Sep 10, 2024 424B5 Filing
Sep 10, 2024 8-K Current Report
Aug 12, 2024 S-8 Securities to be offered to employees in employee benefit plans
Aug 8, 2024 8-K Current Report
Aug 8, 2024 10-Q Quarterly Report
Jul 15, 2024 8-K Current Report